Phathom Pharmaceuticals, Inc. (PHAT)
Stock Price:
$39.36 USD
-0.23 (-0.58%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.14B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-207.36M |
| Shares Out |
28.96M |
| EPS (ttm) |
-23.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$39.36 |
| Previous Close |
$39.59 |
| Change ($) |
-0.23 |
| Change (%) |
-0.58% |
| Day's Open |
38.90 |
| Day's Range |
38.25 - 40.00 |
| Day's Volume |
87,400 |
| 52-Week Range |
18.51 - 64.54 |
More Stats
| Market Cap |
1.14B |
| Enterprise Value |
941.19M |
| Earnings Date (est) |
Nov 30, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
28.96M |
| Float |
13.29M |
| EPS (basic) |
-10.14 |
| EPS (diluted) |
-23.02 |
| FCF / Share |
-1.58 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
817,818 |
| Short Ratio |
15.99 |
| Short % of Float |
6.16% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.39 |
| Revenue |
n/a |
| Operating Income |
-62.37M |
| Net Income |
-207.36M |
| Free Cash Flow |
-52.12M |
| Net Cash |
198.85M |
| Net Cash / Share |
6.87 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-23.11% |
| ROE |
-398.62% |
| ROIC |
-2,104.60% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
1 |
Analyst Consensus: Overweight
Price Target
$38.33*
(-2.62% downside)
Low
32.0
Current: $39.36
High
45.0
Target: 38.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -106 | -1.23 |
| Net Income | -255 | -1.29 |
| Shares Outstanding | 11.37 | 6.05 |
| Earnings Per Share | -22.45 | -0.21 |
| Operating Cash Flow | -36.51 | -1.02 |
| Capital Expenditures | -0.13 | - |
| Free Cash Flow | -36.64 | -1.02 |
| Cash & Equivalents | 244 | 0.88 |
| Total Debt | 23.57 | 1.95 |
| Net Cash / Debt | 220 | -1.07 |
| Assets | 257 | 0.90 |
| Liabilities | 29.22 | 2.19 |
| Book Value | 228 | -1.29 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Phathom Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
25 |
| CEO |
Terrie Curran |
Stock Information
| Ticker Symbol |
PHAT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PHAT |
| IPO Date |
October 25, 2019 |
Description
Phathom Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.